Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results Meeting Abstract
| Authors: | Pant, S.; Schuler, M. H.; Iyer, G.; Doi, T.; Qin, S.; Tabernero, J.; Arnold, D.; Gutierrez, M.; Prenen, H.; Folprecht, G.; Winter, H.; Cosman, R.; Zibetti Dal Molin, G.; Xia, Q.; Najmi, S.; Hammond, C.; Thomas, S.; Triantos, S.; Sweiti, H.; Loriot, Y. |
| Abstract Title: | Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: Expansion cohort results |
| Meeting Title: | 2023 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2023 Jan 19-21 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.4_suppl.610 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 610 -- Entry Date: In Process -- Revision Date: 20230127 -- Publication Type: Article -- Supplement Title: 2/1/2023 Supplement 1 -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
